| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
BDY FL-X, SE targets primary amines (-NH₂) on biomolecules such as proteins, peptides, and antibodies through its NHS ester functional group. The compound does not target specific enzymes or receptors but rather serves as a covalent labeling reagent that attaches the BODIPY FL fluorophore to amine-containing biomolecules. The C3 alkyl spacer reduces potential interactions between the fluorophore and the conjugated biomolecule.
|
|---|---|
| ln Vitro |
Stock solutions for BODIPY FL-X, a succinimidyl ester dye, are made in DMSO. Subsequently, the dye is diluted to a final concentration of 10 μM in 0.1 M sodium bicarbonate buffer (pH 8.3).
BDY FL-X, SE exhibits high fluorescence quantum yield and high extinction coefficient and is relatively insensitive to pH changes. The dye serves as a viable alternative to FAM, Cy2, or FITC for green fluorescence labeling applications. The green fluorescence provides bright and photostable labeling suitable for various fluorescence-based detection and imaging techniques. |
| ln Vivo |
No significant in vivo activity data has been reported for BDY FL-X, SE as a therapeutic agent, as the compound is primarily utilized as a fluorescent labeling reagent for research applications. The compound is intended for research use only.
|
| Enzyme Assay |
In vitro labeling assays for BDY FL-X, SE involve incubating the NHS ester with amine-containing biomolecules in appropriate buffers (typically pH 7-9). The reaction proceeds through nucleophilic attack of the primary amine on the NHS ester carbonyl, forming a stable amide bond and releasing N-hydroxysuccinimide as a byproduct. Labeling efficiency can be assessed by measuring the degree of labeling (DOL) using UV-Vis spectroscopy.
|
| Cell Assay |
For in vitro cellular experiments, BDY FL-X, SE is first conjugated to antibodies, peptides, or other targeting ligands via the NHS ester-amine reaction. The labeled conjugates are then purified and added to cell culture medium for incubation with target cells. After washing, cells are analyzed by fluorescence microscopy or flow cytometry to visualize the green fluorescence. The dye is relatively insensitive to pH changes, making it suitable for various cellular environments.
|
| Animal Protocol |
In vivo animal experiments with BDY FL-X, SE are not typically performed as a therapeutic intervention. However, the dye can be used for in vivo imaging applications when conjugated to targeting ligands. The green fluorescence provides bright and photostable labeling for tracking biomolecules in biological samples. Conjugates bearing BDY FL-X, SE can be administered to animal models for tracking biodistribution and target engagement.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of BDY FL-X, SE have not been characterized, as the compound is a research-use fluorescent labeling reagent rather than a drug candidate. The compound has a molecular weight of 502.33 g/mol and a molecular formula of C₂₄H₂₉BF₂N₄O₅. The NHS ester is reactive and should be stored under appropriate conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for BDY FL-X, SE has not been systematically evaluated, as the compound is intended for research applications only and not for therapeutic use. Standard laboratory safety precautions should be observed when handling this chemical reagent. The NHS ester is moisture-sensitive and should be handled under anhydrous conditions.
|
| References |
|
| Additional Infomation |
BODIPY FL-X is a BODIPY dye and pyrrolidone. It is used as a fluorescent dye. It is functionally related to 4,4-difluoro-4-boron-3a,4a-diaza-s-indenbenzene.
BDY FL-X, SE is a green fluorescent dye based on the BODIPY fluorophore, designed for amine labeling with high fluorescence quantum yield and relative insensitivity to pH changes. The dye features a C3 alkyl spacer that reduces potential interactions between the fluorophore and conjugated biomolecule. BDY FL-X, SE serves as a viable alternative to FAM, Cy2, or FITC. The compound has no clinical or therapeutic applications and has not received regulatory approval. |
| Molecular Formula |
C24H29BF2N4O5
|
|---|---|
| Molecular Weight |
502.32
|
| Exact Mass |
502.22
|
| CAS # |
217190-09-5
|
| PubChem CID |
13007361
|
| Appearance |
Yellow to orange solid powder
|
| LogP |
2.814
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
36
|
| Complexity |
1040
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[B-]1(N2C(=CC(=C2C=C3[N+]1=C(C=C3)CCC(=O)NCCCCCC(=O)ON4C(=O)CCC4=O)C)C)(F)F
|
| InChi Key |
AWACOFBGFAKYPF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H29BF2N4O5/c1-16-14-17(2)29-20(16)15-19-8-7-18(30(19)25(29,26)27)9-10-21(32)28-13-5-3-4-6-24(35)36-31-22(33)11-12-23(31)34/h7-8,14-15H,3-6,9-13H2,1-2H3,(H,28,32)
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 6-[3-(2,2-difluoro-10,12-dimethyl-3-aza-1-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-1(12),4,6,8,10-pentaen-4-yl)propanoylamino]hexanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 83.33 mg/mL (165.89 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9908 mL | 9.9538 mL | 19.9076 mL | |
| 5 mM | 0.3982 mL | 1.9908 mL | 3.9815 mL | |
| 10 mM | 0.1991 mL | 0.9954 mL | 1.9908 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
